Fig. 6

Hypofractionated radiotherapy promotes M2-like Ccl8^high macrophages infiltration and leads to poor prognosis. A Kaplan–Meier plots showing worse clinical prognosis in the LUAD and HNSC patients with the higher expression level of the Mac_Ccl8 signature. HR, hazard ratio. B Schematic diagram of the combination treatment with hypofractionated radiotherapy and the Bindarit. The intraperitoneally administration of Bindarit began from day 5 to day 11 post-tumor injection, and radiation treatment was initiated from day 7 to day 9 post-tumor injection. C Growth curves of tumors in LLC-bearing mice in the indicated treatment groups (n = 5 mice/group). Data are presented as mean ± SD with two-way ANOVA test. D Representative examples in the indicated treatment groups of multiplex immunofluorescent labeling F4/80, CD206 and CCL8. Yellow, F4/80, Green, CD206; Red, CCL8; Blue, DAPI. E Percentages of M1 and M2 macrophages in the specific treatment groups analyzed by flow cytometry (n = 3/group). F Representative flow cytometry panels showing M2 macrophages (top) and M1 macrophages (bottom). BI, Bindarit; RT, Radiation therapy; RT + BI, the combination therapy of the radiation and the Bindarit